# HIV-1-infection FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hiv-1-infection

> 16 upcoming FDA catalysts in HIV-1-infection: oral lenacapavir (GILD) on March 2027 (primary completion); oral lenacapavir (GILD) on Mar to Jun 2027 (topline data readout); Yeztugo® (lenacapavir, GILD) on August 2027 (primary completion); Yeztugo® (lenacapavir, GILD) on Aug to Nov 2027 (topline data readout); and 12 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 29, 2025 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | completed | "NCT05502341 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-09-29 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05502341)) |
| October 13, 2025 | [Dor/isl primary completion](https://sec-api.dev/pdufa/dor-isl) | MRK | HIV-1 Infection | completed | "NCT05705349 (DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05705349)) |
| October 27, 2025 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | completed | "NCT06333808 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-11-05." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06333808)) |
| March 16, 2026 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) primary completion](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD | HIV-1-infection | withdrawn | "NCT06613685 (Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2026-03-16 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06613685)) |
| April 17, 2026 | [Isl/len primary completion](https://sec-api.dev/pdufa/isl-len) | GILD | HIV-1-infection | completed | "NCT06630286 (Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-17 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06630286)) |
| April 23, 2026 | [Isl/len primary completion](https://sec-api.dev/pdufa/isl-len) | GILD | HIV-1-Infection | completed | "NCT06630299 (Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-23 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06630299)) |
| October 21, 2026 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | completed | "NCT05502341 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-09-29 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05502341?tab=results)) |
| November 5, 2026 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | completed | "NCT06333808 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-11-05." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06333808?tab=results)) |
| March 2027 | [Oral lenacapavir primary completion](https://sec-api.dev/pdufa/oral-lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT06749054 (Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06749054)) |
| Mar to Jun 2027 | [Oral lenacapavir topline data readout](https://sec-api.dev/pdufa/oral-lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT06749054 (Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06749054)) |
| August 2027 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT07645287 (A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07645287)) |
| Aug to Nov 2027 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT07645287 (A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07645287)) |
| August 2027 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1 Infection | scheduled | "NCT07841990 (Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07841990)) |
| Aug to Nov 2027 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1 Infection | scheduled | "NCT07841990 (Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07841990)) |
| January 2028 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) primary completion](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD | HIV-1-Infection | scheduled | "NCT06544733 (Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544733)) |
| Jan to Apr 2028 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) topline data readout](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD | HIV-1-Infection | scheduled | "NCT06544733 (Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544733)) |
| March 2029 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT07683000 (Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07683000)) |
| Mar to Jun 2029 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT07683000 (Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07683000)) |
| May to Aug 2029 | [MK-8591A topline data readout](https://sec-api.dev/pdufa/mk-8591a) | MRK | HIV-1 Infection | scheduled | "NCT04776252 (Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-05-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04776252)) |
| May 2029 | [MK-8591A primary completion](https://sec-api.dev/pdufa/mk-8591a) | MRK | HIV-1 Infection | scheduled | "NCT04776252 (Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-05-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04776252)) |
| July 2030 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT06532656 (Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-07 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06532656)) |
| Jul to Oct 2030 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT06532656 (Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-07 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06532656)) |
| October 2030 | [Yeztugo® (lenacapavir) primary completion](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT07708727 (Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07708727)) |
| Oct 2030 to Jan 2031 | [Yeztugo® (lenacapavir) topline data readout](https://sec-api.dev/pdufa/lenacapavir) | GILD | HIV-1-infection | scheduled | "NCT07708727 (Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07708727)) |

## Drugs

- [Yeztugo® (lenacapavir)](https://sec-api.dev/pdufa/lenacapavir) (GILD)
- [Dor/isl](https://sec-api.dev/pdufa/dor-isl) (MRK)
- [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate)](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) (GILD)
- [Isl/len](https://sec-api.dev/pdufa/isl-len) (GILD)
- [Oral lenacapavir](https://sec-api.dev/pdufa/oral-lenacapavir) (GILD)
- [MK-8591A](https://sec-api.dev/pdufa/mk-8591a) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hiv-1-infection.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HIV-1-infection FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hiv-1-infection

```bibtex
@misc{secapidev_indications_hiv_1_infection_20261116,
  title        = {HIV-1-infection FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hiv-1-infection}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hiv_1_infection_20261116","title":"HIV-1-infection FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hiv-1-infection","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
